(TGTX) TG Therapeutics - Ratings and Ratios
Anti-CD20 Antibody, BTK Inhibitor, Bispecific Antibody, Relapsing Multiple Sclerosis, Lymphoma/Leukemia
TGTX EPS (Earnings per Share)
TGTX Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 69.9% |
| Value at Risk 5%th | 92.1% |
| Relative Tail Risk | -19.90% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.02 |
| Alpha | -9.73 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.607 |
| Beta | 0.598 |
| Beta Downside | 0.433 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.91% |
| Mean DD | 32.32% |
| Median DD | 28.54% |
Description: TGTX TG Therapeutics November 06, 2025
TG Therapeutics (NASDAQ:TGTX) is a commercial-stage biopharma focused on B-cell mediated diseases, primarily in the United States but with a growing international footprint. Its flagship product, BRIUMVI (ublituximab), is an anti-CD20 monoclonal antibody approved for adult relapsing multiple sclerosis (RMS) subtypes, including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS.
The pipeline builds on the same anti-CD20 platform with Ublituximab IV for RMS, a covalent BTK inhibitor (TG-1701) that is orally administered, and a bispecific CD47/CD19 antibody (TG-1801) aimed at hematologic malignancies. The company also holds a suite of licensing and collaboration agreements with partners such as LFB Biotechnologies, Ildong Pharmaceutical, Jiangsu Hengrui, and Checkpoint Therapeutics to co-develop and commercialize its assets.
From the most recent 10-K (FY 2023), TG Therapeutics reported net product revenue of approximately $140 million, driven largely by BRIUMVI sales, and a cash runway of roughly 12 months at current burn rates. The firm’s R&D spend was $115 million, reflecting heavy investment in late-stage trials for TG-1701 and TG-1801. As of the latest market data, the company’s market capitalization sits near $2.5 billion, with a forward-looking price-to-sales multiple of about 18×, well above the biotech sector average of 12×.
Key economic drivers include the expanding global MS market-projected to exceed $15 billion by 2028-and the broader BTK inhibitor space, which is expected to grow at a CAGR of ~10% as clinicians seek oral alternatives to intravenous therapies. However, uncertainties remain around the ability of TG-1701 to differentiate itself from established BTK competitors (e.g., ibrutinib, acalabrutinib) and the regulatory timeline for TG-1801. For a deeper quantitative assessment of TG Therapeutics’ valuation and risk profile, a review of the detailed analytics on ValueRay can provide useful context.
TGTX Stock Overview
| Market Cap in USD | 4,922m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 1995-12-14 |
| Return 12m vs S&P 500 | -9.46% |
| Analyst Rating | 4.43 of 5 |
TGTX Dividends
Currently no dividends paidTGTX Growth Ratios
| CAGR 3y | 57.93% |
| CAGR/Max DD Calmar Ratio | 0.72 |
| CAGR/Mean DD Pain Ratio | 1.79 |
| Current Volume | 1330k |
| Average Volume | 1658.9k |
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income (447.5m TTM) > 0 and > 6% of Revenue (6% = 31.9m TTM) |
| FCFTA -0.07 (>2.0%) and ΔFCFTA -2.06pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 83.28% (prev 169.6%; Δ -86.27pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.07 (>3.0%) and CFO -70.1m <= Net Income 447.5m (YES >=105%, WARN >=100%) |
| Net Debt (171.3m) to EBITDA (115.2m) ratio: 1.49 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.82 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (161.0m) change vs 12m ago 0.18% (target <= -2.0% for YES) |
| Gross Margin 85.33% (prev 88.25%; Δ -2.92pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 66.03% (prev 45.18%; Δ 20.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.22 (EBITDA TTM 115.2m / Interest Expense TTM 27.3m) >= 6 (WARN >= 3) |
Altman Z'' -2.50
| (A) 0.43 = (Total Current Assets 599.8m - Total Current Liabilities 156.8m) / Total Assets 1.03b |
| (B) -1.08 = Retained Earnings (Balance) -1.11b / Total Assets 1.03b |
| warn (B) unusual magnitude: -1.08 — check mapping/units |
| (C) 0.14 = EBIT TTM 115.0m / Avg Total Assets 805.5m |
| (D) -2.64 = Book Value of Equity -1.11b / Total Liabilities 417.8m |
| Total Rating: -2.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.07
| 1. Piotroski 4.0pt = -1.0 |
| 2. FCF Yield -1.38% = -0.69 |
| 3. FCF Margin -13.21% = -4.95 |
| 4. Debt/Equity 0.42 = 2.41 |
| 5. Debt/Ebitda 1.49 = 0.98 |
| 6. ROIC - WACC (= 6.66)% = 8.33 |
| 7. RoE 133.2% = 2.50 |
| 8. Rev. Trend 72.51% = 5.44 |
| 9. EPS Trend 60.89% = 3.04 |
What is the price of TGTX shares?
Over the past week, the price has changed by +2.31%, over one month by -11.10%, over three months by +11.79% and over the past year by +4.69%.
Is TG Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of TGTX is around 28.71 USD . This means that TGTX is currently overvalued and has a potential downside of -7.39%.
Is TGTX a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 0
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the TGTX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 44.3 | 42.9% |
| Analysts Target Price | 44.3 | 42.9% |
| ValueRay Target Price | 31.8 | 2.6% |
TGTX Fundamental Data Overview November 17, 2025
P/E Trailing = 11.1913
P/E Forward = 23.6407
P/S = 9.2528
P/B = 8.1051
Beta = 2.008
Revenue TTM = 531.9m USD
EBIT TTM = 115.0m USD
EBITDA TTM = 115.2m USD
Long Term Debt = 245.3m USD (from longTermDebt, last quarter)
Short Term Debt = 1.16m USD (from shortTermDebt, last fiscal year)
Debt = 253.7m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = 171.3m USD (from netDebt column, last quarter)
Enterprise Value = 5.10b USD (4.92b + Debt 253.7m - CCE 74.1m)
Interest Coverage Ratio = 4.22 (Ebit TTM 115.0m / Interest Expense TTM 27.3m)
FCF Yield = -1.38% (FCF TTM -70.2m / Enterprise Value 5.10b)
FCF Margin = -13.21% (FCF TTM -70.2m / Revenue TTM 531.9m)
Net Margin = 84.13% (Net Income TTM 447.5m / Revenue TTM 531.9m)
Gross Margin = 85.33% ((Revenue TTM 531.9m - Cost of Revenue TTM 78.0m) / Revenue TTM)
Gross Margin QoQ = 82.59% (prev 86.58%)
Tobins Q-Ratio = 4.98 (Enterprise Value 5.10b / Total Assets 1.03b)
Interest Expense / Debt = 2.65% (Interest Expense 6.72m / Debt 253.7m)
Taxrate = -1409 % (out of range, set to none) (-365.0m / 25.9m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 3.82 (Total Current Assets 599.8m / Total Current Liabilities 156.8m)
Debt / Equity = 0.42 (Debt 253.7m / totalStockholderEquity, last quarter 607.2m)
Debt / EBITDA = 1.49 (Net Debt 171.3m / EBITDA 115.2m)
Debt / FCF = -2.44 (negative FCF - burning cash) (Net Debt 171.3m / FCF TTM -70.2m)
Total Stockholder Equity = 335.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 43.65% (Net Income 447.5m / Total Assets 1.03b)
RoE = 133.2% (Net Income TTM 447.5m / Total Stockholder Equity 335.8m)
RoCE = 19.79% (EBIT 115.0m / Capital Employed (Equity 335.8m + L.T.Debt 245.3m))
RoIC = 14.48% (EBIT 115.0m / (Assets 1.03b - Curr.Liab 156.8m - Cash 74.1m))
WACC = 7.82% (E(4.92b)/V(5.18b) * Re(8.22%) + (debt cost/tax rate unavailable))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.07%
Fair Price DCF = unknown (Cash Flow -70.2m)
EPS Correlation: 60.89 | EPS CAGR: 557.2% | SUE: 4.0 | # QB: 1
Revenue Correlation: 72.51 | Revenue CAGR: 1492 % | SUE: 0.23 | # QB: 0
Additional Sources for TGTX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle